StockGlow

Genmab A/S (GMAB.CO)

Develops antibody drugs to treat cancers, blood disorders, and autoimmune diseases

1,908.00+0.00%Healthcare
Compare GMAB.CO with
StockGlow Score
81
Bullish
BearishBullish
1 year ago+37.6%

The outlook

Genmab trades at 1908 with strong analyst backing—15 analysts average a "Strong Buy" rating. The stock sits solidly above its 50- and 200-day averages and roughly midway through its 52-week range, while the average analyst price target sits about 25% above the current level.

What’s behind the score

Analyst consensusStrong Buy — 1.5 avg of 15 analysts
Price trendAbove its 50- & 200-day averages
52-week range62% of the way from its 52-week low to high
Price targetAvg target +25% vs current price

Analyst price target

~12-month · 15 analysts
2,392.08average target+25.4% vs now
Now 1,908.00
Low 1,400.00High 2,972.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$117.14B
52-wk high
2,257.00
52-wk low
1,337.00
50-day avg
1,743.05
200-day avg
1,864.00
Trailing P/E
22.1

Similar stocks

DSV.CODSV A/S$1,402.50+0.32%AMBU-B.COAmbu A/S$72.60+3.57%BAVA.COBavarian Nordic A/S$178.40+2.00%GN.COGN Store Nord A/S$93.72-0.19%ZEAL.COZealand Pharma A/S$305.90+2.31%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy